-DOCSTART- -X- O
We -X- _ O
show -X- _ O
that -X- _ O
a -X- _ O
model -X- _ O
antigen -X- _ O
, -X- _ O
ovalbumin -X- _ O
( -X- _ O
OVA -X- _ O
) -X- _ O
, -X- _ O
can -X- _ O
be -X- _ O
chemically -X- _ O
conjugated -X- _ O
to -X- _ O
the -X- _ O
exterior -X- _ O
of -X- _ O
a -X- _ O
small -X- _ O
heat -X- _ O
shock -X- _ O
protein -X- _ O
( -X- _ O
sHsp -X- _ O
) -X- _ O
cage -X- _ O
that -X- _ O
has -X- _ O
structural -X- _ O
similarities -X- _ O
to -X- _ O
virus-like -X- _ O
particles -X- _ O
( -X- _ O
VLPs -X- _ O
) -X- _ O
. -X- _ O
OVA-sHsp -X- _ B-Intervention
conjugation -X- _ I-Intervention
efficiency -X- _ O
was -X- _ O
dependent -X- _ O
upon -X- _ O
the -X- _ O
stoichiometry -X- _ O
and -X- _ O
the -X- _ O
length -X- _ O
of -X- _ O
the -X- _ O
small -X- _ O
molecule -X- _ O
linker -X- _ O
utilized -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
attachment -X- _ O
position -X- _ O
on -X- _ O
the -X- _ O
sHsp -X- _ O
cage. -X- _ O
When -X- _ O
conjugated -X- _ B-Intervention
OVA-sHsp -X- _ I-Intervention
was -X- _ O
delivered -X- _ B-Outcome
intranasally -X- _ I-Outcome
to -X- _ I-Outcome
naïve -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
resulting -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
OVA -X- _ I-Outcome
was -X- _ I-Outcome
accelerated -X- _ I-Outcome
and -X- _ I-Outcome
intensified -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
OVA-specific -X- _ I-Outcome
IgG1 -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
apparent -X- _ I-Outcome
within -X- _ I-Outcome
5 -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
a -X- _ I-Outcome
single -X- _ I-Outcome
immunizing -X- _ I-Outcome
dose -X- _ I-Outcome
, -X- _ I-Outcome
illustrating -X- _ I-Outcome
its -X- _ I-Outcome
utility -X- _ I-Outcome
for -X- _ I-Outcome
vaccine -X- _ I-Outcome
development. -X- _ I-Outcome
If -X- _ I-Outcome
animals -X- _ I-Outcome
were -X- _ I-Outcome
pretreated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
disparate -X- _ I-Outcome
VLP -X- _ I-Outcome
, -X- _ I-Outcome
P22 -X- _ I-Outcome
( -X- _ I-Outcome
a -X- _ I-Outcome
non-replicative -X- _ I-Outcome
bacteriophage -X- _ I-Outcome
capsid -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
before -X- _ I-Outcome
OVA-sHsp -X- _ I-Outcome
conjugate -X- _ I-Outcome
immunization -X- _ I-Outcome
, -X- _ I-Outcome
OVA-specific -X- _ I-Outcome
IgG1 -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
apparent -X- _ I-Outcome
already -X- _ I-Outcome
by -X- _ I-Outcome
4 -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
a -X- _ I-Outcome
single -X- _ I-Outcome
immunizing -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
conjugate -X- _ I-Outcome
in -X- _ I-Outcome
OVA-naïve -X- _ I-Outcome
mice. -X- _ I-Outcome
Additionally -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
mice -X- _ I-Outcome
pretreated -X- _ I-Outcome
with -X- _ I-Outcome
P22 -X- _ I-Outcome
produced -X- _ I-Outcome
high -X- _ I-Outcome
titer -X- _ I-Outcome
mucosal -X- _ I-Outcome
IgA -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
isotype-switched -X- _ I-Outcome
OVA-specific -X- _ I-Outcome
serum -X- _ I-Outcome
IgG. -X- _ I-Outcome
Similarly -X- _ I-Outcome
, -X- _ I-Outcome
sHsp -X- _ I-Outcome
pretreatment -X- _ I-Outcome
enhanced -X- _ I-Outcome
the -X- _ I-Outcome
accumulation -X- _ I-Outcome
of -X- _ I-Outcome
lung -X- _ I-Outcome
germinal -X- _ I-Outcome
center -X- _ I-Outcome
B -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
T -X- _ I-Outcome
follicular -X- _ I-Outcome
helper -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
polymeric -X- _ I-Outcome
Ig -X- _ I-Outcome
receptor -X- _ I-Outcome
expression -X- _ I-Outcome
, -X- _ I-Outcome
priming -X- _ I-Outcome
the -X- _ I-Outcome
lungs -X- _ I-Outcome
for -X- _ I-Outcome
subsequent -X- _ I-Outcome
IgG -X- _ I-Outcome
and -X- _ I-Outcome
IgA -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
challenge. -X- _ I-Outcome
Thus -X- _ I-Outcome
, -X- _ I-Outcome
sHsp -X- _ I-Outcome
nanoparticles -X- _ I-Outcome
elicited -X- _ I-Outcome
quick -X- _ I-Outcome
and -X- _ I-Outcome
intense -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
these -X- _ I-Outcome
accelerated -X- _ I-Outcome
responses -X- _ I-Outcome
could -X- _ I-Outcome
similarly -X- _ I-Outcome
be -X- _ I-Outcome
induced -X- _ I-Outcome
to -X- _ I-Outcome
antigen -X- _ I-Outcome
chemically -X- _ I-Outcome
conjugated -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
sHsp. -X- _ I-Outcome
Pretreatment -X- _ I-Outcome
of -X- _ I-Outcome
mice -X- _ I-Outcome
with -X- _ I-Outcome
P22 -X- _ I-Outcome
further -X- _ I-Outcome
accelerated -X- _ I-Outcome
the -X- _ I-Outcome
onset -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
OVA-sHsp -X- _ I-Outcome
, -X- _ O
demonstrating -X- _ O
the -X- _ O
utility -X- _ O
of -X- _ O
conjugating -X- _ O
antigens -X- _ O
to -X- _ O
VLPs -X- _ O
for -X- _ O
pre- -X- _ O
, -X- _ O
or -X- _ O
possibly -X- _ O
post-exposure -X- _ O
prophylaxis -X- _ O
of -X- _ O
lung -X- _ O
, -X- _ O
all -X- _ O
without -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
adjuvant -X- _ O
. -X- _ O

